Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
Respiratory syncytial virus (RSV) accounts for about 20% of all respiratory infections in children below the age of 5 y. It is associated with up to 63% of all acute respiratory infections and up to 81% of all viral lower respiratory tract infections causing hospitalization in infants and young chil...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2017-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|